New codes needed for chronically ill pts

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 6
Volume 17
Issue 6

I recently attended a healthcare conference titled “Leadership Summit on Evidence-Based Medicine” in Alexandria, Virginia. As you know, private industry, insurance companies, and the government are trying to develop an evidence-based medicine approach to help check the growth of healthcare expenditures.

I recently attended a healthcare conference titled “Leadership Summit on Evidence-Based Medicine” in Alexandria, Virginia. As you know, private industry, insurance companies, and the government are trying to develop an evidence-based medicine approach to help check the growth of healthcare expenditures.

The esteemed speakers’ overarching conclusion was that there is currently no independent measurement of evidence-based medicine.

As you can guess, I was one of only a few speakers representing the interests of oncologists. After 3 days, I finally had an opportunity to comment. From the oncology perspective, my solution was simple: Create level six, seven, and eight E&M codes for chronically ill patient care. These codes could be utilized by any physician in any specialty providing chronic care.

For oncology, these new codes would solve the issue surrounding the failed lobbying for oncology treatment planning codes. Treatment planning never happened-even at our urging with a detailed proposal including documentation. As the AMA RUC Committee has stated in denying the new codes: Oncology treatment planning is recognized in the level five services.

These new level six, seven, and eight codes for the management of chronically ill patients would allow oncologists to be compensated for the complexity of their services and would clearly define the outcome measurements needed for applying evidence-based medicine to the treatment of these patients.

Recent Videos
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Non-Hodgkin lymphoma and other indolent forms of disease may require sequencing new treatments for years or decades, said Scott Huntington, MD, MPH, MSc.
Fixed-duration therapy may be more suitable for younger patients, while continuous therapy may benefit those who are older with more comorbidities.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Andrezj Jakubowiak, MD, PhD, prioritizes KRd-based regimens for the treatment of high-risk newly diagnosed disease in the post-transplant setting.
2 KOLs are featured in this series.
Related Content